Marco Vignetti
Haematologist who presides over GIMEMA, Italy's adult haematological malignancies cooperative group, and co-authored its chemotherapy-free Ph+ ALL trial.
Overview
Marco Vignetti is President of Fondazione GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto), the Italian cooperative group that runs multicentre trials in adult haematological malignancies. He has co-authored landmark GIMEMA studies including the dasatinib-blinatumomab trial in Philadelphia-positive acute lymphoblastic leukaemia and the description of NPM1 mutations in normal-karyotype AML.
| Title | Journal | Year |
|---|---|---|
| Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults | New England Journal of Medicine | 2020 |
| Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype | New England Journal of Medicine | 2005 |
Pages like this
not linked directly; found by shared links- PersonAntonio Cuneo
Shares GIMEMA and the tags leadership, clinician-scientist, leukaemia.
- PersonNorbert Vey
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tags leadership, clinician-scientist.
- PersonJames R. Downing
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tags leadership, clinician-scientist.
- PersonBrian Huntly
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.
- PersonKonstanze Döhner
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.
- PersonHubert Serve
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.
- PersonThomas Kindler
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.
- PersonMartin Bornhäuser
Shares Acute myeloid leukaemia and the tags leadership, clinician-scientist, leukaemia.